de Araújo Lima, Leandro
Feio-dos-Santos, Ana Cecília
Belangero, Sintia Iole
Gadelha, Ary
Bressan, Rodrigo Affonseca
Salum, Giovanni Abrahão
Pan, Pedro Mario
Moriyama, Tais Silveira
Graeff-Martins, Ana Soledade
Tamanaha, Ana Carina
Alvarenga, Pedro
Krieger, Fernanda Valle
Fleitlich-Bilyk, Bacy
Jackowski, Andrea Parolin
Brietzke, Elisa
Sato, João Ricardo
Polanczyk, Guilherme Vanoni
Mari, Jair de Jesus
Manfro, Gisele Gus
do Rosário, Maria Conceição
Miguel, Eurípedes Constantino
Puga, Renato David
Tahira, Ana Carolina
Souza, Viviane Neri
Chile, Thais
Gouveia, Gisele Rodrigues
Simões, Sérgio Nery
Chang, Xiao
Pellegrino, Renata
Tian, Lifeng
Glessner, Joseph T.
Hashimoto, Ronaldo Fumio
Rohde, Luis Augusto
Sleiman, Patrick M.A.
Hakonarson, Hakon
Brentani, Helena
Article History
Received: 21 July 2015
Accepted: 23 February 2016
First Online: 7 March 2016
Change Date: 24 May 2016
Change Type: Update
Change Details: A correction has been published and is appended to both the HTML and PDF versions of this paper. The error has not been fixed in the paper.
Competing interests
: Ary Gadelha, Pedro Mario Pan, and Tais Silveira Moriyama have received continuous medical education support from Astra Zeneca, Eli-Lilly and Janssen-Cilag. Guilherme Vanoni Polanczyk has aided as a speaker and/or consultant to Eli-Lilly, Novartis, and Shire Pharmaceuticals, developed educational material to Janssen-Cilag, and receives unrestricted research support from Novartis. Maria Conceição do Rosário has worked for the last five years as a speaker for the companies Novartis and Shire. Rodrigo A. Bressan was on the speakers’ bureau and/or acted as consultant for Eli-Lilly, Janssen-Cilag, Novartis, Lundbek and Roche in the last three years. Luis Augusto Rohde was on the speakers’ bureau and/or acted as consultant for Eli-Lilly, Janssen-Cilag, Novartis and Shire in the last three years. The ADHD and Juvenile Bipolar Disorder Outpatient Programs chaired by LAR received unrestricted educational and research support from the following pharmaceutical companies in the last three years: Abbott; Eli-Lilly; Janssen-Cilag; Novartis; Shire. All other authors declare no potential conflicts of interest.